Literature DB >> 33710345

Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?

Christina Tsien1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33710345      PMCID: PMC8041323          DOI: 10.1093/neuonc/noab029

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  Late Effects of Radiation Prime the Brain Microenvironment for Accelerated Tumor Growth.

Authors:  Chong Duan; Ruimeng Yang; Liya Yuan; John A Engelbach; Christina I Tsien; Keith M Rich; Sonika M Dahiya; Tanner M Johanns; Joseph J H Ackerman; Joel R Garbow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-30       Impact factor: 7.038

3.  Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.

Authors:  Solmaz Sahebjam; Peter A Forsyth; Nam D Tran; John A Arrington; Robert Macaulay; Arnold B Etame; Christine M Walko; Theresa Boyle; Edwin N Peguero; Michael Jaglal; Sepideh Mokhtari; Heiko Enderling; Natarajan Raghunand; Tyra Gatewood; Wendy Long; Jennifer L Dzierzeski; Brittany Evernden; Timothy Robinson; Melissa C Wicklund; Sungjune Kim; Zachary J Thompson; Dung-Tsa Chen; Prakash Chinnaiyan; Hsiang-Hsuan Michael Yu
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

4.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

Authors:  Jing Zeng; Alfred P See; Jillian Phallen; Christopher M Jackson; Zineb Belcaid; Jacob Ruzevick; Nicholas Durham; Christian Meyer; Timothy J Harris; Emilia Albesiano; Gustavo Pradilla; Eric Ford; John Wong; Hans-Joerg Hammers; Dimitris Mathios; Betty Tyler; Henry Brem; Phuoc T Tran; Drew Pardoll; Charles G Drake; Michael Lim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-22       Impact factor: 7.038

5.  Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Authors:  Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan
Journal:  Nat Med       Date:  2019-06       Impact factor: 53.440

6.  Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.

Authors:  Lakshmi Nayak; Annette M Molinaro; Katherine Peters; Jennifer L Clarke; Justin T Jordan; John de Groot; Leia Nghiemphu; Thomas Kaley; Howard Colman; Christine McCluskey; Sarah Gaffey; Timothy R Smith; David J Cote; Mariano Severgnini; Jennifer H Yearley; Qing Zhao; Wendy M Blumenschein; Dan G Duda; Alona Muzikansky; Rakesh K Jain; Patrick Y Wen; David A Reardon
Journal:  Clin Cancer Res       Date:  2020-11-16       Impact factor: 12.531

7.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

  7 in total
  1 in total

1.  Ropivacaine represses the proliferation, invasion, and migration of glioblastoma via modulating the microRNA-21-5p/KAT8 regulatory NSL complex subunit 2 axis.

Authors:  Zexiang Deng; Yanping Jian; Hongwei Cai
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.